What is NEWCELX LTD's earnings per share (EPS)?

NEWCELX LTD (NLSPW) reported diluted earnings per share of $-2.63 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

NEWCELX LTD Financials

NLSPW

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE December

This page shows NEWCELX LTD (NLSPW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

NEWCELX LTD passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

2.15x

For every $1 of reported earnings, NEWCELX LTD generates $2.15 in operating cash flow (-$4.3M OCF vs -$2.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-97.2x

NEWCELX LTD earns $-97.2 in operating income for every $1 of interest expense (-$4.4M vs $45K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$4.4M

YoY+62.9%

NEWCELX LTD's EBITDA was -$4.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 62.9% from the prior year.

Net Income

-$2.0M

YoY+83.7%

NEWCELX LTD reported -$2.0M in net income in fiscal year 2024. This represents an increase of 83.7% from the prior year.

EPS (Diluted)

$-2.63

NEWCELX LTD earned $-2.63 per diluted share (EPS) in fiscal year 2024. This represents an increase of 79.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$4.3M

NEWCELX LTD generated -$4.3M in free cash flow in fiscal year 2024, representing cash available after capex.

Cash & Debt

$1.7M

YoY+85.5%

5Y CAGR+49.9%

NEWCELX LTD held $1.7M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

NEWCELX LTD had 3M shares outstanding in fiscal year 2024. This represents a decrease of 91.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-140.9%

NEWCELX LTD's ROE was -140.9% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$422K

YoY-92.9%

5Y CAGR-14.0%

NEWCELX LTD invested $422K in research and development in fiscal year 2024. This represents a decrease of 92.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$4K

NEWCELX LTD invested $4K in capex in fiscal year 2024, funding long-term assets and infrastructure.

NLSPW Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$422K-92.9%	$5.9M-34.2%	$9.0M+51.6%	$5.9M+5844.4%	$100K-88.9%	$898K
SG&A Expenses	$3.2M-45.5%	$5.9M-9.3%	$6.5M+9.5%	$5.9M+170.1%	$2.2M-33.3%	$3.3M
Operating Income	-$4.4M+62.9%	-$11.8M+23.7%	-$15.5M-30.5%	-$11.9M-415.8%	-$2.3M+45.2%	-$4.2M
Interest Expense	$45K-62.4%	$120K+26.0%	$95K+97.9%	$48K-44.6%	$87K+8649.2%	$992
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.0M+83.7%	-$12.2M+26.2%	-$16.5M-38.1%	-$11.9M-317.5%	-$2.9M+47.5%	-$5.4M
EPS (Diluted)	$-2.63	$-12.75+62.0%	$-33.52-3252.0%	$-1.00-143.9%	$-0.41	N/A

Metric	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NLSPW Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$2.2M+20.9%	$1.8M-80.1%	$9.3M+60.9%	$5.8M+375.8%	$1.2M+74.0%	$696K
Current Assets	$2.2M+22.1%	$1.8M-80.3%	$9.2M+61.6%	$5.7M+2809.4%	$197K-48.5%	$382K
Cash & Equivalents	$1.7M+85.5%	$898K-90.0%	$8.9M+64.8%	$5.4M+5695.7%	$94K-57.5%	$220K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$827K-92.3%	$10.7M+78.1%	$6.0M+14.8%	$5.2M-48.8%	$10.2M+48.5%	$6.9M
Current Liabilities	$827K-89.6%	$7.9M+135.7%	$3.4M+39.8%	$2.4M-66.6%	$7.2M+78.5%	$4.0M
Long-Term Debt	N/A	N/A	N/A	N/A	$113K	N/A
Total Equity	$1.4M+115.9%	-$8.8M-369.2%	$3.3M+504.9%	$542K+106.0%	-$9.0M-45.6%	-$6.2M
Retained Earnings	-$74.4M-5.8%	-$70.4M-20.9%	-$58.2M-39.6%	-$41.7M-40.1%	-$29.8M-10.6%	-$26.9M

Metric	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Total Assets	$4.3M+94.2%	$2.2M+87.1%	$1.2M-35.4%	$1.8M-18.7%	$2.3M-75.5%	$9.3M+350.7%	$2.1M-64.3%	$5.8M
Current Assets	$4.0M+81.3%	$2.2M+86.6%	$1.2M-34.6%	$1.8M-18.8%	$2.2M-75.7%	$9.2M+357.2%	$2.0M-64.7%	$5.7M
Cash & Equivalents	$3.1M+84.5%	$1.7M+201.3%	$553K-38.4%	$898K-45.6%	$1.7M-81.5%	$8.9M+560.8%	$1.4M-75.1%	$5.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.5M+76.0%	$827K-92.1%	$10.5M-2.0%	$10.7M+62.9%	$6.6M+9.4%	$6.0M-1.7%	$6.1M+16.8%	$5.2M
Current Liabilities	N/A	$827K-89.3%	$7.7M-2.5%	$7.9M+103.5%	$3.9M+15.9%	$3.4M-1.5%	$3.4M+41.9%	$2.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$2.9M+105.0%	$1.4M+115.2%	-$9.3M-4.9%	-$8.8M-106.1%	-$4.3M-230.7%	$3.3M+181.2%	-$4.0M-845.1%	$542K
Retained Earnings	-$74.8M-0.5%	-$74.4M-2.8%	-$72.4M-2.9%	-$70.4M-6.9%	-$65.8M-13.1%	-$58.2M-15.6%	-$50.3M-20.7%	-$41.7M

NLSPW Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$4.3M+55.9%	-$9.7M+30.2%	-$13.9M+7.1%	-$14.9M-1947.8%	-$729K-283.9%	-$190K
Capital Expenditures	$4K	N/A	N/A	$40K	N/A	N/A
Free Cash Flow	-$4.3M	N/A	N/A	-$15.0M	N/A	N/A
Investing Cash Flow	-$4K	N/A	N/A	-$40K	N/A	N/A
Financing Cash Flow	$5.0M+208.5%	$1.6M-90.6%	$17.4M-14.5%	$20.3M+3939.1%	$504K+23.6%	$407K
Dividends Paid	$2.1M	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NLSPW Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-140.9%	N/A	-502.8%+1699.7pp	-2202.5%	N/A	N/A
Return on Assets	-88.7%+570.4pp	-659.1%-481.3pp	-177.8%+29.4pp	-207.2%+28.9pp	-236.2%+546.0pp	-782.2%
Current Ratio	2.69+2.5	0.23-2.5	2.75+0.4	2.38+2.4	0.03-0.1	0.09
Debt-to-Equity	0.59+1.8	-1.21-3.0	1.83-7.8	9.63+9.6	-0.01+1.1	-1.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	N/A	2.69+2.5	0.15-0.1	0.23-0.3	0.58-2.2	2.75+2.2	0.59-1.8	2.38
Debt-to-Equity	0.50-0.1	0.59+1.7	-1.13+0.1	-1.21+0.3	-1.53-3.4	1.83+3.3	-1.51-11.1	9.63
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

NKGen Biotech NKGNW

Tevogen Bio TVGNW

Briacell Therapeutics Corp BCTXW

Estrella Immunopharma ESLAW

Pasithea Therapeutics Corp KTTAW

Frequently Asked Questions

Is NEWCELX LTD profitable?

No, NEWCELX LTD (NLSPW) reported a net income of -$2.0M in fiscal year 2024.

What is NEWCELX LTD's EBITDA?

NEWCELX LTD (NLSPW) had EBITDA of -$4.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is NEWCELX LTD's return on equity (ROE)?

NEWCELX LTD (NLSPW) has a return on equity of -140.9% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is NEWCELX LTD's free cash flow?

NEWCELX LTD (NLSPW) generated -$4.3M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is NEWCELX LTD's operating cash flow?

NEWCELX LTD (NLSPW) generated -$4.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are NEWCELX LTD's total assets?

NEWCELX LTD (NLSPW) had $2.2M in total assets as of fiscal year 2024, including both current and long-term assets.

What are NEWCELX LTD's capital expenditures?

NEWCELX LTD (NLSPW) invested $4K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does NEWCELX LTD spend on research and development?

NEWCELX LTD (NLSPW) invested $422K in research and development during fiscal year 2024.

How many shares does NEWCELX LTD have outstanding?

NEWCELX LTD (NLSPW) had 3M shares outstanding as of fiscal year 2024.

What is NEWCELX LTD's current ratio?

NEWCELX LTD (NLSPW) had a current ratio of 2.69 as of fiscal year 2024, which is generally considered healthy.

What is NEWCELX LTD's debt-to-equity ratio?

NEWCELX LTD (NLSPW) had a debt-to-equity ratio of 0.59 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is NEWCELX LTD's return on assets (ROA)?

NEWCELX LTD (NLSPW) had a return on assets of -88.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is NEWCELX LTD's cash runway?

Based on fiscal year 2024 data, NEWCELX LTD (NLSPW) had $1.7M in cash against an annual operating cash burn of $4.3M. This gives an estimated cash runway of approximately 5 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is NEWCELX LTD's Piotroski F-Score?

NEWCELX LTD (NLSPW) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are NEWCELX LTD's earnings high quality?

NEWCELX LTD (NLSPW) has an earnings quality ratio of 2.15x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can NEWCELX LTD cover its interest payments?

NEWCELX LTD (NLSPW) has an interest coverage ratio of -97.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.